Related Experiment Video

Updated: Aug 9, 2026

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
12:37

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

Published on: February 9, 2016

Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol

T Wendt1, R van der Does, R Schräder

  • 1University Clinic, Department of Cardiology, Frankfurt, F.R.G.

Journal of Cardiovascular Pharmacology
|January 1, 1987
PubMed

Insights

Carvedilol, unlike propranolol, does not increase vascular resistance or decrease cardiac output during exercise. This beta-blocker may offer advantages for patients with coronary artery disease and peripheral vascular conditions.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Coronary heart disease (CHD) management often involves beta-blockers.
  • Understanding the differential hemodynamic effects of various beta-blockers is crucial for patient care.

Purpose of the Study:

  • To compare the acute hemodynamic effects of carvedilol and propranolol in patients with CHD.
  • To investigate the impact of these drugs on systemic and pulmonary hemodynamics, cardiac output, and lower limb blood flow during rest and exercise.

Main Methods:

  • A randomized, double-blind study involving 16 male patients with CHD.
  • Oral administration of 50 mg carvedilol versus 40 mg propranolol.
  • Measurement of systemic/pulmonary pressures, heart rate, cardiac index, and lower limb blood flow at rest, during, and after exercise.

Main Results:

  • Carvedilol did not increase systemic/pulmonary resistance or decrease cardiac output, unlike propranolol.
  • Carvedilol did not increase pulmonary capillary wedge pressure during exercise.
  • Postexercise lower limb blood flow significantly increased with carvedilol, but not with propranolol.

Conclusions:

  • Carvedilol's vasodilating properties differentiate its hemodynamic profile from propranolol.
  • These acute effects suggest carvedilol may be beneficial in treating peripheral occlusive artery disease, hypertension, and coronary vasospasm.

More Related Videos

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

O-Ring Aortic Banding Versus Traditional Transverse Aortic Constriction for Modeling Pressure Overload-Induced Cardiac Hypertrophy09:24

O-Ring Aortic Banding Versus Traditional Transverse Aortic Constriction for Modeling Pressure Overload-Induced Cardiac Hypertrophy

Published on: October 6, 2022

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...